Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells

Background and aim As a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems. Because the mechanism controlling sorafenib-resistance is not well understood, this study focused on the connection between tumor characteristics and the Nrf2 signaling pathway in a sorafenib-resistant HCC cell line. Methods A sorafenib-resistant HCC cell line (Huh7) was developed by increasing the dose of sorafenib in the culture medium until the target concentration was reached. Cell morphology, migration/invasion rates, and expression of stemness-related and ATP-binding cassette (ABC) transporter genes were compared between sorafenib-resistant Huh7 cells and parental Huh7 cells. Next, a small interfering RNA was used to knock down Nrf2 expression in sorafenib-resistant Huh7 cells, after which cell viability, stemness, migration, and ABC transporter gene expression were examined again. Results Proliferation, migration, and invasion rates of sorafenib-resistant Huh7 cells were significantly increased relative to the parental cells with or without sorafenib added to the medium. The expression levels of stemness markers and ABC transporter genes were up-regulated in sorafenib-resistant cells. After Nrf2 was knocked down in sorafenib-resistant cells, cell migration and invasion rates were reduced, and expression levels of stemness markers and ABC transporter genes were reduced. Conclusion Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant HCC cells.

[1]  Yao Fu,et al.  Cooperation between NRF2-mediated transcription and MDIG-dependent epigenetic modifications in arsenic-induced carcinogenesis and cancer stem cells. , 2021, Seminars in cancer biology.

[2]  M. Kwak,et al.  The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance , 2021, Archives of Pharmacal Research.

[3]  J. Yun,et al.  NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma , 2020, Cancer Letters.

[4]  Xiaolu Yang,et al.  TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway , 2020, Nature Communications.

[5]  A. I. Rojo,et al.  Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas , 2020, Redox biology.

[6]  N. Samadi,et al.  The Role of Nrf2 signaling in cancer stem cells: from stemness and self-renewal to tumorigenesis and chemoresistance. , 2019, Life sciences.

[7]  Jia Hu,et al.  Pxr- and Nrf2- mediated induction of ABC transporters by heavy metal ions in zebrafish embryos. , 2019, Environmental pollution.

[8]  I. Ng,et al.  Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC , 2019, Nature Communications.

[9]  M. Parola,et al.  Of FACT complex and oxidative stress response: a KEAP1/NRF2-dependent novel mechanism sustaining hepatocellular carcinoma progression , 2019, Gut.

[10]  Ya Cao,et al.  Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target , 2019, BMC Cancer.

[11]  Y. Morine,et al.  Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction , 2018, Cell Communication and Signaling.

[12]  In-geun Ryoo,et al.  High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling , 2018, Cell Death & Disease.

[13]  A. Yu,et al.  Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells , 2018, Drug Metabolism and Disposition.

[14]  A. Bosserhoff,et al.  Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance , 2017, Gut.

[15]  G. Cassinelli,et al.  Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. , 2017, European journal of medicinal chemistry.

[16]  Cheng Chen,et al.  Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. , 2017, Cancer letters.

[17]  Y. Seong,et al.  Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells , 2017, Antioxidants.

[18]  L. Qu,et al.  Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma , 2017, Oncogene.

[19]  B. Zhai,et al.  Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells , 2017, Molecular oncology.

[20]  Yang Zhang,et al.  NRBP2 Overexpression Increases the Chemosensitivity of Hepatocellular Carcinoma Cells via Akt Signaling. , 2016, Cancer research.

[21]  P. Pascuzzi,et al.  EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes. , 2016, Journal of hepatology.

[22]  Brandon Da Silva,et al.  NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer , 2016, Cell.

[23]  W. El-Deiry,et al.  Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC) , 2016, Clinical Cancer Research.

[24]  J. Wang,et al.  Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5+ liver cancer initiating cells by suppressing negative regulators of β-catenin signaling , 2015, Oncogene.

[25]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[26]  Takafumi Suzuki,et al.  Toward clinical application of the Keap1-Nrf2 pathway. , 2013, Trends in pharmacological sciences.

[27]  M. McMahon,et al.  Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. , 2010, Antioxidants & redox signaling.

[28]  J. Llovet,et al.  Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. , 2010, Annual review of medicine.

[29]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[30]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[31]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[32]  Y. Kan,et al.  Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Yu,et al.  Bioengineered NRF 2-siRNA is effective to interfere with NRF 2 pathways and improve chemosensitivity of human cancer cells , 2017 .

[34]  C. Gonçalves,et al.  [Hepatocellular carcinoma]. , 1988, Arquivos de gastroenterologia.